
News|Articles|June 1, 2007
From the 56th Annual Scientific Session of the American College of Cardiology: EVEREST: Tolvaptan improves symptoms, volume status in patients with acute decompensated HF but offers no long-term impact
The investigational vasopressin receptor antagonist tolvaptan had no long-term impact on clinical events in patients hospitalized with acute decompensated heart failure (ADHF), but the agent did improve symptoms and volume status over the short term, according to results presented at the 56th annual ACC scientific session.
Advertisement
Newsletter
Get the latest industry news, event updates, and more from Managed healthcare Executive.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
7 things you need to know about the PBM reforms signed into law this week
2
TrumpRx launches; some experts question its long-term value
3
PBM reform. It has finally happened
4
FDA issues draft guidance on MRD and complete response as primary endpoints for accelerated multiple myeloma drug approvals
5























